Drug-labels.com

Neostigmine Omega Product Monograph

Updated:
Facts
Status:
Prescription (Rx)
Strength:
2.5 mg, 1 mg, 0.5 mg
Active ingredient:
ATC code:
Similar drugs:

Source: Health Canada – Drug Product Database (DPD) and product monographs · About this document

Product Monograph - Neostigmine Omega

SYMPTOMS AND TREATMENT OF OVERDOSAGE

Symptoms: Muscarinic and nicotinic effects (see ADVERSE REACTIONS). Distinguish from myasthenic crisis with edrophonium chloride, if necessary.

Treatment: Control muscarinic effects with IV atropine, followed by intramuscular (IM) atropine every 2 to 4 hours. Assist ventilation and treat convulsions or shock if necessary.

For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.

DOSAGE AND ADMINISTRATION

Intestinal atony, postoperative: Prophylaxis: 250 mcg subcutaneous (SC) or IM before or immediately after operation, repeated every 4 to 6 hours SC. Treatment: 500 mcg SC, IM (or possibly IV) repeated at intervals of 4 to 5 hours.

Urinary Retention: Prophylaxis: 250 mcg as for intestinal atony. Treatment: 500 mcg SC or IM and apply heat to the lower abdomen. If urination does not occur within one hour, the patient should be catheterized. After the patient has voided, continue the 500 mcg injections at 3-hour intervals for at least 5 additional injections.

Curare Antagonist (to neutralize the effect of curare in surgical anesthesia and shock therapy): 0.5 to 2 mg IV. Atropine sulfate 0.6 to 1.2 mg IV should also be given.

Prescribing Information - Neostigmine Omega Page 4 of 4

DOSAGE FORMS, COMPOSITION, AND PACKAGING

0.5 mg/mL: Each mL contains Neostigmine Methylsulfate 0.5 mg, Phenol 0.45%, Sodium Acetate, Acetic Acid and Sodium Hydroxide as a buffer to adjust the pH and Water for Injection. Available in multidose vials of 1 mL and 10 mL, boxes of 10.

1 mg/mL: Each mL contains Neostigmine Methylsulfate 1 mg, Phenol 0.45%, Sodium Acetate, Acetic Acid and Sodium Hydroxide as a buffer to adjust the pH and Water for Injection. Available in multidose vials of 10 mL, boxes of 10.

2.5 mg/mL: Each mL contains Neostigmine Methylsulfate 2.5 mg, Phenol 0.45%, Sodium Acetate, Acetic Acid and Sodium Hydroxide as a buffer to adjust the pH and Water for Injection. Available in multidose vials of 5 mL, boxes of 10.

STORAGE AND STABILITY

Store between 15 and 30°C. Protect from light. Multiple use. Discard 28 days after initial use.

Do not use product if mixture (solution) shows haziness, particulate matter, discolouration, or leakage.

REFERENCES

  1. 1) Neostigmine Methylsulfate Injection USP Prescribing Information, Sandoz Canada Inc., Date of revision: November 12, 2007.

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02387166

Revision date stated in the text: May 24, 2012

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Neostigmine Omega

Rx or OTC
Prescription (Rx)?
DIN 02387166, 02230592, 02230593
Schedule(s) PRESCRIPTION
Active ingredient(s) Neostigmine methylsulfate
Dosage form(s) Solution, Liquid
Route(s) of administration Subcutaneous, Intravenous, Intramuscular
Drug class (WHO ATC)
  1. N Nervous system drugs
    1. N07 Other nervous system drugs
      1. N07A Parasympathomimetics
        1. N07AA Anticholinesterase parasympathomimetics
          1. N07AA01 Neostigmine
Company OMEGA LABORATORIES LIMITED
Current status Marketed
Strengths and forms
DIN Strength Dosage form(s) Current status
02387166 2.5 MG Solution Marketed April 17, 2013
02230592 1 MG Liquid Marketed July 23, 1999
02230593 0.5 MG Liquid Marketed July 23, 1999

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.